NANOSTRUCTURED LIPID CARRIER (NLC) DRUG DELIVERY SYSTEMS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS

摘要

The invention relates to Nanostructured lipid carrier (NLC) drug delivery systems of antioxidant for treatment of neurodegenerative disorders. It particularly relates to the Ubidecarenone (coenzyme Q10) loaded Nanostructured lipid carrier (NLC) drug delivery systems for treatment of neurodegenerative disorders such as Alzheimer"s disease, Parkinson"s disease etc. It also relates to the process for preparation of coenzyme Q10 loaded Nanostructured lipid carrier (NLC) drug delivery systems by solvent diffusion method.The drug delivery system comprises Glyceryl distearate and Glyceryl behenate as solid lipid and Glyceryl triacetate as liquid lipid. The influences of different type of solid lipid and liquid lipid concentration on physiochemical properties of the NLC were characterized. Properties of these carriers such as the particle size, drug loading, drug encapsulation efficiency, drug release, Fourier transform infrared spectroscopy, differential scanning calorimetry behavior were investigated. As a result, the drug encapsulation efficiencies were improved by adding the liquid lipid into the solid lipid of nanoparticles. NLC had higher encapsulation efficiency and drug release. In addition, in vivo study showed that the antioxidant activity of the Ubidecarenone (Co.QlO NLC) was more effective than the Ubidecarenone (Coenzyme Q10) solution form on DPPH scavenging, anti-lipid peroxidation, lowers the effect of amnesia induced by scopolamine and increased bioavailability observed in Cmax, Tmax, and AUC. These results suggest that nanostructured lipid formulation of Coenzyme Q10 has more antioxidant activity than that of solution form and it can be used to reduce the oxidative stress and to increase the antioxidant enzyme activity in many neurodegenerative disorders such as Alzheimer"s disease, Parkinson"s disease etc.